Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Equillium, Inc. EQ

Healthcare — Biotechnology
Dividend Champion (3y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
2.43
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 1 2 1 1 2 — 2 2 — — —
Insider Ownership
54.72%

Capital & Financial Ratios

Market Cap
119.84
Revenue
41.10
Net Income
(18.01)
Free Cash Flow
(20.08)
Net Debt
(57.16)
Current Ratio
23.40
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
5.22
P/B ratio
3.83
Past 5Y EPS Growth
31.13%
This Y EPS Growth
47.44%
Next Y EPS Growth
(11.71%)
Next 5Y EPS Growth
11.40%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 40.87 22.58 30.28 57.16
Receivables 3.74 — — —
Inventory — — — —
Other — — — —
49.35 24.98 31.04 57.98
2023 2024 2025 Q'26
Payables 4.71 2.68 0.76 0.85
ST’ Debt — — — —
Other — — — —
27.57 6.36 2.93 2.48
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’24 10.69 13.85 12.16 4.39
41.10
’23 8.88 9.12 8.87 9.21
36.08
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (4.30) (4.11) — —
—
’25 (8.17) (3.01) (8.43) (3.13)
(22.75)
’24 (8.80) 0.73 (7.66) (3.30)
(19.03)
’23 (7.99) (6.21) (1.91) (5.66)
(21.78)
’22 (12.13) (11.26) (13.06) 27.73
(8.73)
’21 (7.94) (6.99) (7.01) (10.13)
(32.08)
’20 (6.37) (5.08) (4.92) (8.25)
(24.62)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (4.30) (4.18) — —
—
’25 (8.17) (3.01) (8.43) (3.16)
(22.78)
’24 (8.82) 0.67 (7.66) (3.30)
(19.11)
’23 (7.99) (6.21) (1.92) (5.70)
(21.83)
’22 (12.36) (11.31) (13.06) 27.72
(9.01)
’21 (7.94) (7.02) (7.04) (10.13)
(32.14)
’20 (6.38) (5.08) (5.08) (8.28)
(24.83)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.06) (0.04) — —
—
’25 (0.24) (0.16) (0.06) (0.04)
(0.39)
’24 (0.08) 0.01 0.00 (0.16)
(0.23)
’23 (0.11) (0.10) (0.11) (0.07)
(0.38)
’22 (1.17) (0.41) (0.40) 0.08
(1.85)
’21 (0.33) (0.31) (0.35) (0.36)
(1.36)
’20 (0.45) (0.37) (0.31) (0.36)
(1.46)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — ‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡ 0.79 0.45 0.56 0.27 — — —
Low Price
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.38 1.35 3.25 2.35 — — —
High Price
— ‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 36 44 35 14 — — —
Employees
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.44 0.82 1.17 0.00 — — —
Revenue/Emp
— — — — — — 15.76 36.08 41.10 — ‡‡‡‡‡ ‡‡‡‡‡ —
Revenue
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% — — — —
Gross Margin
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (62.43) (12.75) (7.71) (22.40) — — —
EBT
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ (396.14%) (35.35%) (18.75%) 0.00% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (62.43) (13.33) (8.07) (22.40) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.45 (0.61) (0.62) 0.10 — — —
Depreciation
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.47 1.04 1.16 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Revenue/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.85) (0.38) (0.23) (0.39) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.26) (0.63) (0.54) (0.40) — — —
Cash Flow/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.01) 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.27) (0.63) (0.54) (0.40) — — —
Free CF/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.95 0.65 0.54 0.50 — — —
Book Value/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 33.73 34.73 35.36 57.30 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — — 0.00 0.00 0.00 — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — — — — — 0.00 0.70 0.65 — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — — 1.12 1.12 1.39 — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — — 0.00 (0.40) 0.12 — ‡‡‡‡ ‡‡‡‡ —
EV/Sales
— — — — — — 2.92 0.67 (0.25) — — — —
EV/FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (8.73) (21.78) (19.03) (22.75) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.28) (0.05) (0.08) (0.04) — — —
Capex
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (9.01) (21.83) (19.11) (22.78) — — —
FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 44.70 21.78 18.62 28.10 — — —
Working Cap'
— ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.95 — — — — — —
Total Debt
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (62.07) (40.87) (22.57) (30.28) — — —
Net Debt
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.94 22.57 19.06 28.60 — — —
Sh' Equity
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (76.21%) (20.68%) (21.19%) (77.92%) — — —
ROA
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (126.83%) (48.92%) (38.75%) (93.99%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Equillium, Inc. (EQ), a clinical-stage immunology biotech, embodies the sector’s wild ride: from 2018 IPO hype and 2020 pandemic peaks at $27 to 2023 lows of $0.45, now stabilizing around $3 amid improving fundamentals. Revenue exploded from near-zero pre-2022 to $41.1 million in 2024, with 100% gross margins, efficiency soaring (revenue per employee up 168%), and losses slashed 88% to -$7.7 million EBT. Yet, heavy dilution (shares up 168% since 2017) eroded book value, and the stock decoupled from these gains, lagging the Nasdaq Biotech Index’s rebound—hinting at undervaluation or hidden traps.

Analyst forecasts paint a bifurcated picture: a stark revenue cliff to $8.3 million in 2025-2027 (80% plunge from lumpy milestones), ballooning losses to -$29 million, and EPS tanking to -$0.53, fueling 36% downside risks. Insider selling (142K shares, no buys) amid narrowing losses screams caution, while FCF could worsen 300% and EV/sales spike to 10x, signaling distress or M&A bait.

But contrarians take note: mean targets imply 59% upside (high 155%), powered by itolizumab’s GVHD catalysts, immunology M&A frenzy ($100B+ deals), and 2026 rate cuts reviving VC flows. With net cash fortress and peer-beating margins, EQ could rerate if execution trumps the revenue apocalypse—monitor Q1 2026 earnings for the pivot.

Read full commentary →

Equillium, Inc. (EQ) Latest News

News by impact score

Fine-tune

20 Aug

3 , 5:00 PM
Equillium, Inc. reported its second quarter 2026 financial results. Quarterly earnings reports deliver performance metrics that shape near-term stock valuation and sentiment.

13 Aug

3 , 4:05 PM
Equillium reported second quarter 2026 financial results and recent corporate highlights. Quarterly financial results and corporate updates provide key data for assessing company performance and future outlook.

10 Jun

3 Insider Monkey, 1:45 PM
Analysts express growing confidence in Equillium’s (EQ) lead asset EQ504. Increased analyst confidence in EQ504 may lift short-term investor sentiment and valuation without altering long-term company trajectory.

4 Jun

3 , 8:00 AM
EQ Works expands ClearLake Platform with AI-Powered Audience Segments. Platform expansion via AI features supports product innovation and competitive positioning.

29 May

3 www.marketbeat.com, 11:03 AM
Equillium establishes link between AhR activation and miR-124, advancing EQ504 into Phase 1 trials. EQ504 Phase 1 entry signals pipeline progress with moderate effects on future performance.

13 May

4 GlobeNewswire, 4:01 PM
Equillium, Inc. (EQ) reported first quarter 2026 financial results and corporate highlights. Quarterly financial results combined with corporate highlights signal major updates on operations, pipeline progress, and financial health that could significantly shift investor sentiment and company trajectory.

25 Mar

3 GlobeNewswire, 4:05 PM
Equillium, Inc. (EQ) reported fourth quarter and full-year 2025 financial results, including recent corporate developments and clinical highlights. Financial results and clinical highlights may moderately affect Equillium's performance and investor sentiment without fundamentally altering its trajectory.

13 Mar

4 GlobeNewswire, 8:00 AM
Equillium, Inc. (EQ) announces $35 million financing agreement with RA Capital Management to support clinical development and operations. $35 million financing from RA Capital Management provides critical capital to fuel Equillium's clinical pipeline and extend operational runway, significantly enhancing future prospects and investor confidence.

13 Feb

4 www.marketbeat.com, 1:28 PM
Equillium, Inc. is set to initiate a Phase 1 clinical trial for EQ504, a treatment targeting ulcerative colitis, by mid-year. This development marks a significant step in the company's efforts to expand its product pipeline and address unmet medical needs in inflammatory bowel diseases. The upcoming Phase 1 trial for EQ504 could significantly impact Equillium's future trajectory and investor sentiment in the competitive landscape of ulcerative colitis treatments.

13 Nov

3 GlobeNewswire, 4:05 PM
Equillium, Inc. reported its financial results for the third quarter of 2025, highlighting key operational updates and financial metrics. The company continues to advance its clinical programs and maintain a strong cash position, which supports ongoing research and development efforts. Management expressed optimism about upcoming milestones and the potential impact of their therapeutic candidates on patient care. The financial results and operational updates indicate moderate progress in clinical programs that could influence future performance.

4 Nov

3 GlobeNewswire, 8:30 AM
Equillium, Inc. will participate in several upcoming investor conferences, providing opportunities for engagement with investors and stakeholders. The company aims to discuss its strategic initiatives and updates on its clinical programs, which may enhance visibility and investor interest. Participation in investor conferences can moderately influence investor sentiment and awareness of the company's developments.

22 Oct

3 GlobeNewswire, 8:00 AM
Equillium, Inc. will host a Key Opinion Leader (KOL) event focused on ulcerative colitis on November 5, 2025. This event aims to engage with experts in the field and discuss advancements related to the company's research and development efforts in treating this condition. The KOL event may enhance Equillium's visibility and influence in the ulcerative colitis market, potentially impacting its competitive positioning.

6 Oct

3 GlobeNewswire, 4:02 PM
Equillium, Inc. announced key leadership changes and corporate updates, including the appointment of a new Chief Financial Officer and the establishment of a strategic advisory board. These changes aim to enhance the company's operational efficiency and strategic direction as it advances its clinical programs and prepares for future growth. Leadership changes and strategic updates may influence operational effectiveness and market positioning.

11 Aug

4 , 8:30 AM
Equillium, Inc. announced a financing initiative of up to $50 million aimed at advancing EQ504, a novel aryl hydrocarbon receptor modulator, into clinical trials. This funding is intended to support the development of EQ504, which targets immune-mediated diseases, and is part of the company's strategy to enhance its product pipeline and market position. The financing for EQ504 represents a significant strategic move that could enhance Equillium's product offerings and market competitiveness.

3 , 10:30 AM
Equillium, Inc. (EQ) has been highlighted as one of the most active stocks in the market, indicating increased trading volume and investor interest. This surge in activity may reflect market sentiment or reactions to recent developments related to the company's operations or strategic initiatives. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential interest in the company's future performance.

4 Aug

3 Simply Wall St., 8:04 AM
Equillium, Inc. (EQ) is highlighted as one of three promising penny stocks with a market cap exceeding $20 million. The company focuses on developing therapies for autoimmune and inflammatory diseases, showcasing potential for growth in a competitive market. Investors are encouraged to consider EQ's innovative approach and market positioning as part of their investment strategy. Equillium's focus on innovative therapies may moderately influence its financial performance and competitive positioning.

1 Aug

3 Associated Press Finance, 10:30 AM
Equillium, Inc. (EQ) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent developments and market performance have contributed to its visibility among investors, indicating potential shifts in market sentiment. Increased trading activity suggests a moderately noticeable influence on market sentiment and investor interest.

6 May

4 Business Wire, 8:00 AM
Equillium, Inc. announced multiple poster presentations at the American Association of Immunologists meeting, showcasing EQ504's potential in treating ulcerative colitis. EQ504 demonstrated protective effects against gut damage, enhanced Treg stability, and promoted healing of intestinal epithelial cells. The presentations highlighted EQ504's ability to modulate immune responses and its promising therapeutic potential for patients with ulcerative colitis. EQ504 is a selective AhR modulator with a non-immunosuppressive mechanism, suitable for targeted delivery in treating inflammatory diseases. The presentations indicate significant advancements in EQ504's therapeutic potential, which could alter Equillium's market positioning and investor sentiment.

1 May

4 Business Wire, 8:00 AM
Equillium, Inc. announced the advancement of EQ504, a novel aryl hydrocarbon receptor modulator acquired through the purchase of Ariagen. EQ504 targets the AhR pathway, which is clinically validated for treating skin and gastrointestinal diseases, and has a unique non-immunosuppressive mechanism of action. The company plans to present data on EQ504 at the American Association of Immunologists annual meeting. CEO Bruce Steel emphasized the strategic importance of this asset, acquired with no upfront payment and milestone payments contingent on FDA approval. The drug shows promise for treating conditions like ulcerative colitis and inflammatory lung diseases, with plans for a Phase 1 study pending additional capital. The introduction of EQ504 represents a significant strategic move that could enhance Equillium's product portfolio and market position in immunology.

24 Apr

4 Business Wire, 9:00 AM
Equillium, Inc. received feedback from the U.S. Food and Drug Administration (FDA) regarding its clinical development plans for the treatment of autoimmune diseases. The FDA provided insights on the design of upcoming clinical trials, which Equillium plans to incorporate into its strategy. This guidance is expected to enhance the company's approach to regulatory submissions and product development. FDA feedback can significantly influence clinical trial design and regulatory strategy, impacting future product development and market positioning.

7 Apr

3 Simply Wall St., 1:05 PM
Equillium, Inc. is highlighted as a promising penny stock amid market volatility, focusing on developing treatments for severe autoimmune disorders. The company has a market cap of $16.83 million and reported $41.1 million in annual sales for 2024, despite a net loss of $8.07 million. While it has no debt and sufficient short-term assets, auditors have raised concerns about its ability to continue as a going concern due to financial challenges and cash runway limitations. Equillium's ongoing financial challenges and unprofitability may moderately influence its future performance and market sentiment.

1 Apr

4 , 9:55 AM
Equillium, Inc. (EQ) is showing signs of potential recovery, with analysts suggesting that the stock may be nearing a bottom. Factors contributing to this outlook include recent developments in the company's pipeline and market conditions that could favor a rebound. Investors are encouraged to consider buying the stock now, as it may present a favorable entry point before a possible upward trend. Recent developments and market conditions indicate a significant potential for recovery and improved investor sentiment.

28 Mar

3 Simply Wall St., 7:35 AM
Equillium, Inc. (NASDAQ:EQ) reported full-year 2024 results with revenue of $41.1 million, a 14% increase from FY 2023, and a narrowed net loss of $8.07 million. Earnings per share improved to a loss of $0.23, surpassing analyst estimates for both revenue and EPS by 12% and 39%, respectively. Revenue is projected to grow at an average of 33% annually over the next three years, outpacing the 20% growth forecast for the US Biotechs industry. However, shares have declined 39% in the past week, and there are four warning signs identified for the company, two of which are concerning. Revenue growth and improved earnings indicate a moderately positive influence on Equillium's future performance.

27 Mar

4 www.clinicaltrialsarena.com, 12:49 PM
Equillium plans to file for breakthrough therapy designation for its aGVHD therapy itolizumab despite missing the primary endpoint in a Phase III trial. The trial showed no significant improvement in complete response or overall response rate at 29 days compared to placebo, but a complete response was recorded at day 99. Following the announcement, Equillium's stock dropped 40.7% but has slightly recovered. The company believes long-term outcomes are compelling and aims to position itolizumab as a first-line treatment. The trial involved 158 patients and was conducted in collaboration with the Dana-Farber Cancer Institute. Filing for breakthrough therapy designation could significantly influence Equillium's market position and investor sentiment.

4 Business Wire, 7:00 AM
Equillium, Inc. reported its fourth quarter and full year 2024 financial results, highlighting topline data from the Phase 3 EQUATOR study for itolizumab in treating acute graft-versus-host disease (aGVHD). Although primary endpoints were not met, significant benefits were observed in longer-term outcomes. The company has submitted a request for Breakthrough Therapy designation and plans to discuss Accelerated Approval with the FDA, with feedback expected in May 2025. Financially, Q4 revenue was $4.4 million, down from $9.2 million in 2023, while full-year revenue increased to $41.1 million. The net loss for Q4 was $5.8 million, compared to $2.3 million in the prior year. The submission for Breakthrough Therapy designation and potential Accelerated Approval could significantly impact Equillium's market position and investor sentiment.

4 , 7:00 AM
Equillium, Inc. announced the results of the Phase 3 EQUATOR study, which evaluated Itolizumab as a first-line treatment for patients with acute graft-versus-host disease (aGVHD). The study demonstrated positive outcomes, showing that Itolizumab significantly improved patient responses compared to the control group. These results support the potential of Itolizumab as a new treatment option for aGVHD, which could enhance patient care and expand Equillium's market presence in this therapeutic area. The positive results from the Phase 3 study could significantly enhance Equillium's market position and investor sentiment regarding Itolizumab's potential in treating aGVHD.

21 Feb

4 , 9:55 AM
Equillium, Inc. (EQ) is being highlighted as a strong 'buy the bottom' stock due to its recent price decline and potential for recovery. The company is focused on developing therapies for severe autoimmune and inflammatory diseases, and analysts believe that its innovative pipeline could lead to significant growth. With a favorable market outlook and strategic positioning, Equillium is seen as an attractive investment opportunity for those looking to capitalize on its current low valuation. Equillium's innovative pipeline and strategic positioning could significantly alter its trajectory and investor sentiment.

10 Feb

4 Zacks, 12:00 PM
Equillium, Inc. (EQ) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive earnings outlook. The Zacks rating system, which correlates earnings estimate revisions with stock price movements, suggests that the upgrade reflects improving business fundamentals. For the fiscal year ending December 2024, Equillium is expected to earn -$0.02 per share, a 94.7% change from the previous year, with a 26.9% increase in the Zacks Consensus Estimate over the past three months. The upgrade positions Equillium in the top 20% of Zacks-covered stocks, suggesting potential for higher stock prices in the near term. The upgrade reflects significant improvements in earnings estimates, which are likely to influence investor sentiment and stock performance.

4 Zacks, 8:50 AM
Equillium, Inc. (EQ) is gaining momentum in the stock market, with a recent four-week price change of 22.3% and a 20.7% increase over the past 12 weeks. The stock has a beta of 1.79, indicating high volatility, and a Momentum Score of B, suggesting a favorable entry point for investors. Additionally, EQ is trading at a low Price-to-Sales ratio of 0.66, indicating it is attractively priced despite its momentum. The stock also holds a Zacks Rank #2 (Buy), supported by upward revisions in earnings estimates, making it a strong candidate for investment. Other stocks fitting this profile are also available for consideration. Equillium's strong price momentum and favorable valuation metrics indicate significant potential for future performance.

7 Feb

3 Simply Wall St., 8:11 AM
Equillium, Inc. is highlighted as a promising penny stock with a market cap of $25.15 million, focusing on severe autoimmune disorders. The company has reduced its losses by 9% annually over the past five years and remains debt-free. Recent positive Phase 2 study results for its drug itolizumab in ulcerative colitis treatment show potential, but Equillium faces Nasdaq compliance challenges due to its stock trading below $1.00 per share, possibly necessitating a reverse stock split by June 2025. Positive clinical trial results and ongoing compliance challenges could moderately influence Equillium's market performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us